Current state of the one-eye trial of glaucoma medications: Response

Clinical and Experimental Ophthalmology

Volumn 36, Issue 5, 2008, Pages 493-

  Dayanir, Volkan ^a   Cakmak, Harun ^a   Berkit, Ilker ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; PROSTAGLANDIN DERIVATIVE;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LETTER; MEDICAL RESEARCH; METHODOLOGY; OUTCOME ASSESSMENT; PREDICTION; PRESSURE MEASUREMENT; TIME; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL SYSTEM EXAMINATION;

EID: 50849140155     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2008.01809.x     Document Type: Letter

References (5)

1. Leffler CT, Hennessy A, Farukhi YZ. Current state of the one-eye trial of glaucoma medications. Clin Experiment Ophthalmol 2008; 36: 492-493.
2. Dayanir V, Cakmak H, Berkit I. The one-eye trial and fellow eye response to prostaglandin analogues. Clin Experimental Ophthalmol 2008; 36: 136-41.
3. Leffler CT, Amini L. Interpretation of uniocular and binocular trials of glaucoma medications: An observational case series. BMC Ophthalmol 2007; 7: 17.
4. Realini T, Fechtner RD, Atreides SP, Gollance S. The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology 2004; 111: 421-6.
5. Chaudhary OR. The monocular trial: Does response to initial glaucoma therapy in one eye predict the response in the fellow eye? Thesis. Yale University School of Medicine, 2007.